RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

This study is testing whether a drug that blocks a protein called RAGE can protect the heart from the damaging effects of chemotherapy in women with early-stage breast cancer. Chemotherapy drugs like doxorubicin can cause long-term heart damage, and this trial aims to find a way to prevent that. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with stage I-III breast cancer (any receptor status) - You are scheduled to receive one of several qualifying chemotherapy regimens that include doxorubicin (AC-based) or other standard combinations - You have not received prior chemotherapy, radiation, or systemic therapy for this cancer - Your blood counts and organ function are within acceptable ranges - You are in reasonably good health (ECOG performance status 0-2) **You may NOT be eligible if...** - You have already received chemotherapy or radiation for breast cancer or any prior cancer - You have significant pre-existing heart disease - You are pregnant or breastfeeding - You have severe kidney or liver problems Talk to your doctor to see if this trial is right for you.